Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05188352
Other study ID # BVUsozyilmaz09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date July 2018

Study information

Verified date December 2021
Source Bezmialem Vakif University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Based on clinical experience both physical condition and psychological recovery after surgery are individually variable. Exercise training plays an important part, has been recommended for CABS patients in order to enhance recovery. Regular exercise following CABS has shown that, in addition to the expected improvements in exercise capacity as a result of the surgery itself, patients who participate in cardiac rehabilitation can expect to see additional gains in exercise capacity and risk factor profiles. Exercise training also increases personal self-esteem and self-confidence, can alleviate depression and fear, and increase the sense of well-being. The aim of this study was to examine the effects of supervised aerobic exercise training on pulmonary function, functional capacity, maximal exercise capacity, and anxiety in patients after coronary artery bypass surgery.


Description:

Patients in the training group received supervised aerobic exercise training on the treadmill with the intensity of 60-75% of maximal VO2 for 40-50 minutes, 3 days a week for 8 weeks in a cardiac rehabilitation unit. Work-load was gradually increased during eight-week period. Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period. In addition, conventional chest physiotherapy and was instructed to continue their daily physical activity program at home patients in this group Patients in the control group received no aerobic exercise training but were asked to continue their chest physiotherapy and daily physical activity program at home. The same researcher, who was blind to the group allocation, were evaluated all patients for pulmonary functions, respiratory muscle strength and submaximal functional capacity, exercise capacity, and anxiety level initially and after 8 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender Male
Age group 35 Years to 70 Years
Eligibility Inclusion Criteria: - Male gender, - CABG surgery performed in the last one month, - Patients with negative exercise test (on the 30 days after discharge). Exclusion Criteria: - Valve surgery, - Perioperative myocardial infarction assessed by electrocardiographic (ECG) and creatine kinase isoenzyme changes, - Postoperative angina, diabetes mellitus, chronic renal failure, unstable angina, intermittent claudication, heart valve dysfunction (moderate or severe), severe cardiac arrhythmias, -Presence of symptoms at rest or with minimal exertion, - Chronic obstructive pulmonary disease (>70% FEV1/FVC), and - Any disorder that might influence exercise performance physically (e.g. severe back pain, history stroke).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chest physiotherapy
The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
Aerobic exercise training
A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2. Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bezmialem Vakif University

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline maximum inspiratory pressure at 8 weeks. Change from baseline Maximum Inspiratory Pressure (MIP) at 8 weeks. Respiratory muscle strength was measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MIP measurement is a non-invasive technique. [ Time Frame: Eight weeks ]
Primary Change from baseline maximum expiratory pressure at 8 weeks Change from baseline Maximum Expiratory Pressure (MEP) at 8 weeks. Respiratory muscle strength was measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MEP measurement is a non-invasive technique. [ Time Frame: Eight weeks ]
Primary Maximal exercise capacity The incremantal, symptom-limited cardiopulmonary exercise test (CPET) was used to assess exercise capacity.
Symptom-limited maximal exercise test with oxygen consumption measurement (peak VO2) (Minjhard Oxycon-3) on the treadmill using a Modified Bruce protocol.
[ Time Frame: Eight weeks ]
Secondary Change from baseline distance covered in six-minute walk test at 8 weeks. Change from baseline functional capacity test at 8 weeks. Functional capacity was assessed by the 6 minute walking test. The test was performed according to American Thoracic Society (ATS) criteria. Patients were allowed to rest for 10 minutes before the test. Heart rate, blood pressure, respiratory frequency, oxygen saturation, fatigue and dyspnea perception were recorded before and after the test. Walking distance was calculated. [ Time Frame: Eight weeks ]
Secondary Change from baseline Forced Vital Capacity (FVC) at 8 weeks Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 8 weeks. FVC was evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. [ Time Frame: Eight weeks ]
Secondary Change from baseline Forced Expiratory Volume in 1 second (FEV1) at 8 weeks . Change from baseline Forced Expiratory Volume 1 second (FEV1) in respiratory function at 8 weeks. FEV1 was evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. [ Time Frame: Eight weeks ]
Secondary Change from baseline Forced Expiratory flow from between 25% to 75% of Vital Capacity at 8 weeks. Change from baseline Forced Expiratory flow from between 25% to 75% of Vital Capacity at 8 weeks.
FMF was evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
[ Time Frame: Eight weeks ]
Secondary Change from baseline anxiety level at 8 weeks. Anxiety level was evaluated by STAI-I and II. [ Time Frame: Eight weeks ]
Secondary Change from baseline maximal oxygen consumption(VO2max) level at 8 weeks Respiratory parameters were continuously measured by using computerized 'Minjhard Oxycon-3'. Measurements were performed in each 30 second, before, during and after exercise test and during each recovery period for five minutes parameters measured. [ Time Frame: Eight weeks ]
Secondary Change from baseline maximal respiratory minute volume (VE), level at 8 weeks Respiratory parameters were continuously measured by using computerized 'Minjhard Oxycon-3'. Measurements were performed in each 30 second, before, during and after exercise test and during each recovery period for five minutes parameters measured [ Time Frame: Eight weeks ]
Secondary Change from baseline VO2max/kg level at 8 weeks Respiratory parameters were continuously measured by using computerized 'Minjhard Oxycon-3'. Measurements were performed in each 30 second, before, during and after exercise test and during each recovery period for five minutes parameters measured [ Time Frame: Eight weeks ]
Secondary Change from baseline maximal oxygen pulse (O2pulse) level at 8 weeks O2 pulse value was calculated from VO2 value which was divided to (by) heart rate at that minute. [ Time Frame: Eight weeks ]
Secondary Change from baseline maximal MET level at 8 weeks Respiratory parameters were continuously measured by using computerized 'Minjhard Oxycon-3'. Measurements were performed in each 30 second, before, during and after exercise test and during each recovery period for five minutes parameters measured [ Time Frame: Eight weeks ]
See also
  Status Clinical Trial Phase
Recruiting NCT05139108 - TEE Monitoring and the Incidence of Postoperative Acute Kidney Injury in Coronary Artery Bypass Grafting
Recruiting NCT04523064 - iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Completed NCT01467232 - IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting Phase 2
Completed NCT04631809 - Computed Tomography Coronary Angiography in Patients With a Previous Coronary Artery Bypass Graft Surgery Trial N/A
Completed NCT00073580 - Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Phase 3
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Completed NCT00303641 - Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients Phase 1
Completed NCT03823521 - Observational Study to Investigate the Effects of Training on the Administration of Cardioplexolâ„¢ Phase 3
Terminated NCT00789399 - A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis N/A
Completed NCT02592824 - Glutamate for Metabolic Intervention in Coronary Surgery II Phase 3
Not yet recruiting NCT05079724 - Acute Kidney Injury After Cardiac Surgery
Withdrawn NCT04379947 - Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice
Terminated NCT00858936 - Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery Phase 2
Recruiting NCT01386229 - A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery Phase 4
Completed NCT00653042 - Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA Phase 2
Completed NCT00318227 - Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients N/A
Completed NCT00372671 - Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation Phase 3
Completed NCT00209521 - Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery Phase 2
Not yet recruiting NCT05396690 - Safety and Efficacy of Remimazolam in OPCAB Surgery N/A